GridAI Technologies Corp. Overview
GRDX market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 5.11
- H
- 5.30
- L
- 4.75
- C
- 4.75
- Vol
- 1,703.00
Daily history from May 22, 2024
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $5.11
- Previous Close
- $5.48
- Day High
- $5.30
- Day Low
- $4.75
- 52 Week High
- $6.83
- 52 Week Low
- $1.87
- 7 Day Return
- -13.95%
- 30 Day Return
- +15.01%
- 90 Day Return
- +71.17%
- 1 Year Return
- +15.57%
- Daily Notional Volume
- $8.1K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.95 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.73 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -17,634.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.87 – $6.93 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $33.4M · P/B 0.66.